TCM
CYTK icon

Tradewinds Capital Management’s Cytokinetics CYTK Stock Holding History

Tradewinds Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-215
Closed -$14.2K – 726
2026
Q1 		$14.2K Hold
215
– – ﹤0.01% 358
2025
Q4 		$13.7K Hold
215
– – ﹤0.01% 352
2025
Q3 		$11.8K Hold
215
– – ﹤0.01% 351
2025
Q2 		$7.1K Hold
215
– – ﹤0.01% 383
2025
Q1 		$8.64K Buy
+215
New +$9.88K ﹤0.01% 373

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tradewinds Capital Management's CYTK Position: Q2 2026 in Review

Tradewinds Capital Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 215 shares — an estimated $14.2K sold.

Tradewinds Capital Management first reported a position in CYTK in Q1 2025 and held it in 5 quarters. The position peaked at $14.2K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Tradewinds Capital Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Tradewinds Capital Management sold 215 Cytokinetics shares in Q2 2026, an estimated $14.2K.
  • Tradewinds Capital Management first reported a position in Cytokinetics in Q1 2025 and held it in 5 quarters.
  • Tradewinds Capital Management's Cytokinetics position peaked at $14.2K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Tradewinds Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.